Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Yoshiya TanakaTsutomu TakeuchiSakae TanakaAtsushi KawakamiManabu IwasakiYeong Wook SongYi-Hsing ChenJames Cheng-Chung WeiSang-Heon LeeMitsuhiro RokudaHiroyuki IzutsuSatoshi UshijimaYuichiro KanekoRio AkazawaTeruaki ShiomiEmi YamadaPublished in: Annals of the rheumatic diseases (2019)
NCT02308163.